Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart.

Ihlo CA, Lauritzen T, Sturis J, Skyggebjerg O, Christiansen JS, Laursen T.

Diabet Med. 2011 Feb;28(2):230-6. doi: 10.1111/j.1464-5491.2010.03149.x.

PMID:
21219436
2.
4.

Impaired absorption of insulin aspart from lipohypertrophic injection sites.

Johansson UB, Amsberg S, Hannerz L, Wredling R, Adamson U, Arnqvist HJ, Lins PE.

Diabetes Care. 2005 Aug;28(8):2025-7. No abstract available.

PMID:
16043749
5.

Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.

Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL.

Diabetes Care. 1998 Oct;21(10):1627-31.

PMID:
9773721
6.

A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes.

Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM; Insulin Aspart Pediatric Pump Study Group.

Diabetes Care. 2008 Feb;31(2):210-5. Epub 2007 Nov 5.

PMID:
17989308
7.

Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Lindholm A, Jacobsen LV.

Clin Pharmacokinet. 2001;40(9):641-59. Review.

PMID:
11605714
8.

A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.

Thorisdottir RL, Parkner T, Chen JW, Ejskjaer N, Christiansen JS.

Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):216-21. doi: 10.1111/j.1742-7843.2008.00355.x. Epub 2009 Jan 20.

9.

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.

Bode B, Weinstein R, Bell D, McGill J, Nadeau D, Raskin P, Davidson J, Henry R, Huang WC, Reinhardt RR.

Diabetes Care. 2002 Mar;25(3):439-44.

PMID:
11874927
10.

Insulin pump therapy in pregnant women with type 1 diabetes mellitus.

Roman G.

Rom J Intern Med. 2004;42(2):465-8. No abstract available.

PMID:
15529637
11.

Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes.

Parkner T, Laursen T, Vestergaard ET, Hartvig H, Smedegaard JS, Lauritzen T, Christiansen JS.

Diabet Med. 2008 May;25(5):585-91. doi: 10.1111/j.1464-5491.2008.02418.x.

PMID:
18445172
12.

Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group.

Diabetes Care. 2005 Mar;28(3):533-8.

PMID:
15735183
13.

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB.

Diabetes. 2000 Dec;49(12):2142-8.

PMID:
11118018
15.

Bolus calculator improves long-term metabolic control and reduces glucose variability in pump-treated patients with Type 1 diabetes.

Lepore G, Dodesini AR, Nosari I, Scaranna C, Corsi A, Trevisan R.

Nutr Metab Cardiovasc Dis. 2012 Aug;22(8):e15-6. doi: 10.1016/j.numecd.2012.04.001. Epub 2012 Jun 4. No abstract available.

PMID:
22673770
16.

Dose-response relationship of insulin glulisine in subjects with type 1 diabetes.

Becker RH, Frick AD, Nosek L, Heinemann L, Rave K.

Diabetes Care. 2007 Oct;30(10):2506-7. Epub 2007 Aug 3. No abstract available.

PMID:
17675541
17.

Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes.

Porcellati F, Rossetti P, Ricci NB, Pampanelli S, Torlone E, Campos SH, Andreoli AM, Bolli GB, Fanelli CG.

Diabetes Care. 2007 May;30(5):1261-3. Epub 2007 Feb 15. No abstract available.

PMID:
17303785
18.

A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control.

DeVries JH, Snoek FJ, Kostense PJ, Masurel N, Heine RJ; Dutch Insulin Pump Study Group.

Diabetes Care. 2002 Nov;25(11):2074-80.

PMID:
12401759
19.

Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 Diabetes treated by means of an insulin pump.

Chlup R, Zapletalová J, Seckar P, Chlupová L, Táncosová S, Reznícková M.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Jul;148(1):27-32.

20.

[Metabolic control in labile type I diabetes with conventional insulin therapy, basal bolus insulin therapy using pens and continuous subcutaneous insulin infusion with the pump].

Biesenbach G, Grafinger P, Kaiser W, Stuby U, Zazgornik J.

Med Klin (Munich). 1988 May 27;83(12):398-401. German. No abstract available.

PMID:
3043159

Supplemental Content

Support Center